CAREDX INC (CDNA) Stock Fundamental Analysis
NASDAQ:CDNA • US14167L1035
18.79 USD
-0.01 (-0.05%)
At close: Feb 23, 2026
18.79 USD
0 (0%)
After Hours: 2/23/2026, 8:00:03 PM
CDNA gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 521 industry peers in the Biotechnology industry. CDNA has an excellent financial health rating, but there are some minor concerns on its profitability. CDNA is not priced too expensively while it is growing strongly. Keep and eye on this one!
1. Profitability
1.1 Basic Checks
- In the past year CDNA was profitable.
- CDNA had a positive operating cash flow in the past year.
- CDNA had negative earnings in 4 of the past 5 years.
- The reported operating cash flow has been mixed in the past 5 years: CDNA reported negative operating cash flow in multiple years.
1.2 Ratios
- CDNA has a better Return On Assets (14.06%) than 95.20% of its industry peers.
- CDNA has a better Return On Equity (19.53%) than 95.39% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.06% | ||
| ROE | 19.53% | ||
| ROIC | N/A |
ROA(3y)-14.72%
ROA(5y)-10.93%
ROE(3y)-25.57%
ROE(5y)-18.01%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- Looking at the Profit Margin, with a value of 16.97%, CDNA belongs to the top of the industry, outperforming 92.71% of the companies in the same industry.
- With an excellent Gross Margin value of 67.62%, CDNA belongs to the best of the industry, outperforming 81.00% of the companies in the same industry.
- In the last couple of years the Gross Margin of CDNA has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 16.97% | ||
| GM | 67.62% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.01%
GM growth 5Y0.9%
2. Health
2.1 Basic Checks
- CDNA does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, CDNA has more shares outstanding
- Compared to 5 years ago, CDNA has more shares outstanding
- CDNA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- An Altman-Z score of 3.57 indicates that CDNA is not in any danger for bankruptcy at the moment.
- With a decent Altman-Z score value of 3.57, CDNA is doing good in the industry, outperforming 69.10% of the companies in the same industry.
- CDNA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 3.57 |
ROIC/WACCN/A
WACC8.72%
2.3 Liquidity
- CDNA has a Current Ratio of 3.03. This indicates that CDNA is financially healthy and has no problem in meeting its short term obligations.
- With a Current ratio value of 3.03, CDNA is not doing good in the industry: 64.11% of the companies in the same industry are doing better.
- CDNA has a Quick Ratio of 2.75. This indicates that CDNA is financially healthy and has no problem in meeting its short term obligations.
- CDNA has a Quick ratio of 2.75. This is in the lower half of the industry: CDNA underperforms 65.83% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.03 | ||
| Quick Ratio | 2.75 |
3. Growth
3.1 Past
- CDNA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 242.11%, which is quite impressive.
- Measured over the past years, CDNA shows a very strong growth in Earnings Per Share. The EPS has been growing by 37.47% on average per year.
- The Revenue has grown by 14.46% in the past year. This is quite good.
- Measured over the past years, CDNA shows a very strong growth in Revenue. The Revenue has been growing by 21.30% on average per year.
EPS 1Y (TTM)242.11%
EPS 3Y23.03%
EPS 5Y37.47%
EPS Q2Q%100%
Revenue 1Y (TTM)14.46%
Revenue growth 3Y4.04%
Revenue growth 5Y21.3%
Sales Q2Q%20.72%
3.2 Future
- CDNA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 38.18% yearly.
- Based on estimates for the next years, CDNA will show a quite strong growth in Revenue. The Revenue will grow by 13.01% on average per year.
EPS Next Y31.72%
EPS Next 2Y30.03%
EPS Next 3Y31.64%
EPS Next 5Y38.18%
Revenue Next Year13.08%
Revenue Next 2Y12.28%
Revenue Next 3Y11.6%
Revenue Next 5Y13.01%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
- Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 28.91, CDNA can be considered very expensive at the moment.
- Based on the Price/Earnings ratio, CDNA is valued cheaper than 93.09% of the companies in the same industry.
- CDNA is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 26.64, which is the current average of the S&P500 Index.
- With a Price/Forward Earnings ratio of 20.58, CDNA is valued on the expensive side.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of CDNA indicates a rather cheap valuation: CDNA is cheaper than 93.09% of the companies listed in the same industry.
- CDNA is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 27.75, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 28.91 | ||
| Fwd PE | 20.58 |
4.2 Price Multiples
- Based on the Price/Free Cash Flow ratio, CDNA is valued cheaper than 94.63% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 26.53 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- CDNA's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- A more expensive valuation may be justified as CDNA's earnings are expected to grow with 31.64% in the coming years.
PEG (NY)0.91
PEG (5Y)0.77
EPS Next 2Y30.03%
EPS Next 3Y31.64%
5. Dividend
5.1 Amount
- CDNA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
18.79
-0.01 (-0.05%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04 2025-11-04/amc
Earnings (Next)02-24 2026-02-24/amc
Inst Owners102.35%
Inst Owner Change-2.38%
Ins Owners2.48%
Ins Owner Change4.78%
Market Cap966.37M
Revenue(TTM)358.00M
Net Income(TTM)60.76M
Analysts77.14
Price Target23.66 (25.92%)
Short Float %11.71%
Short Ratio7.54
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)37.85%
Min EPS beat(2)-18.08%
Max EPS beat(2)93.77%
EPS beat(4)3
Avg EPS beat(4)37.25%
Min EPS beat(4)-18.08%
Max EPS beat(4)93.77%
EPS beat(8)7
Avg EPS beat(8)226.86%
EPS beat(12)11
Avg EPS beat(12)161.16%
EPS beat(16)12
Avg EPS beat(16)102.04%
Revenue beat(2)1
Avg Revenue beat(2)-1.62%
Min Revenue beat(2)-6.22%
Max Revenue beat(2)2.98%
Revenue beat(4)2
Avg Revenue beat(4)-0.98%
Min Revenue beat(4)-6.22%
Max Revenue beat(4)2.98%
Revenue beat(8)6
Avg Revenue beat(8)5.39%
Revenue beat(12)8
Avg Revenue beat(12)5.96%
Revenue beat(16)8
Avg Revenue beat(16)3.77%
PT rev (1m)-3.33%
PT rev (3m)0.87%
EPS NQ rev (1m)0.06%
EPS NQ rev (3m)9.13%
EPS NY rev (1m)-0.46%
EPS NY rev (3m)30.34%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.79%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.57%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 28.91 | ||
| Fwd PE | 20.58 | ||
| P/S | 2.7 | ||
| P/FCF | 26.53 | ||
| P/OCF | 22.71 | ||
| P/B | 3.11 | ||
| P/tB | 4.07 | ||
| EV/EBITDA | N/A |
EPS(TTM)0.65
EY3.46%
EPS(NY)0.91
Fwd EY4.86%
FCF(TTM)0.71
FCFY3.77%
OCF(TTM)0.83
OCFY4.4%
SpS6.96
BVpS6.05
TBVpS4.62
PEG (NY)0.91
PEG (5Y)0.77
Graham Number9.41
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.06% | ||
| ROE | 19.53% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 16.97% | ||
| GM | 67.62% | ||
| FCFM | 10.17% |
ROA(3y)-14.72%
ROA(5y)-10.93%
ROE(3y)-25.57%
ROE(5y)-18.01%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.01%
GM growth 5Y0.9%
F-Score7
Asset Turnover0.83
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 42.35% | ||
| Cap/Sales | 1.71% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | 59.94% | ||
| Current Ratio | 3.03 | ||
| Quick Ratio | 2.75 | ||
| Altman-Z | 3.57 |
F-Score7
WACC8.72%
ROIC/WACCN/A
Cap/Depr(3y)106.55%
Cap/Depr(5y)139.53%
Cap/Sales(3y)4.27%
Cap/Sales(5y)5%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)242.11%
EPS 3Y23.03%
EPS 5Y37.47%
EPS Q2Q%100%
EPS Next Y31.72%
EPS Next 2Y30.03%
EPS Next 3Y31.64%
EPS Next 5Y38.18%
Revenue 1Y (TTM)14.46%
Revenue growth 3Y4.04%
Revenue growth 5Y21.3%
Sales Q2Q%20.72%
Revenue Next Year13.08%
Revenue Next 2Y12.28%
Revenue Next 3Y11.6%
Revenue Next 5Y13.01%
EBIT growth 1Y37.2%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year157.84%
EBIT Next 3Y71.01%
EBIT Next 5Y67.07%
FCF growth 1Y364.87%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y1603.82%
OCF growth 3YN/A
OCF growth 5YN/A
CAREDX INC / CDNA FAQ
What is the ChartMill fundamental rating of CAREDX INC (CDNA) stock?
ChartMill assigns a fundamental rating of 6 / 10 to CDNA.
What is the valuation status of CAREDX INC (CDNA) stock?
ChartMill assigns a valuation rating of 6 / 10 to CAREDX INC (CDNA). This can be considered as Fairly Valued.
What is the profitability of CDNA stock?
CAREDX INC (CDNA) has a profitability rating of 4 / 10.
What are the PE and PB ratios of CAREDX INC (CDNA) stock?
The Price/Earnings (PE) ratio for CAREDX INC (CDNA) is 28.91 and the Price/Book (PB) ratio is 3.11.
Can you provide the financial health for CDNA stock?
The financial health rating of CAREDX INC (CDNA) is 7 / 10.